Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012619
Filing Date
2022-08-08
Accepted
2022-08-08 16:08:10
Documents
69
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20220630x10q.htm   iXBRL 10-Q 1895977
2 EX-31.1 crvs-20220630xex31d1.htm EX-31.1 11896
3 EX-31.2 crvs-20220630xex31d2.htm EX-31.2 11833
4 EX-32.1 crvs-20220630xex32d1.htm EX-32.1 11807
  Complete submission text file 0001558370-22-012619.txt   6945899

Data Files

Seq Description Document Type Size
5 EX-101.SCH crvs-20220630.xsd EX-101.SCH 43359
6 EX-101.CAL crvs-20220630_cal.xml EX-101.CAL 48525
7 EX-101.DEF crvs-20220630_def.xml EX-101.DEF 150322
8 EX-101.LAB crvs-20220630_lab.xml EX-101.LAB 390096
9 EX-101.PRE crvs-20220630_pre.xml EX-101.PRE 287000
63 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20220630x10q_htm.xml XML 1208030
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 221144406
SIC: 2834 Pharmaceutical Preparations